Literature DB >> 8479596

Is ammonia a pathogenetic factor in Alzheimer's disease?

N Seiler.   

Abstract

An attempt was made to review experimental evidence in favor of the idea that ammonia plays a role in dementia of the Alzheimer type (DAT). Hyperammonemia causes biochemical and cellular dysfunctions in the brain, which can be found in brains of DAT patients. The most conspicuous among these findings are astrocytosis, impairment of glucose utilization, and a decreased rate of energy metabolism, and the impairment of neurotransmission, with a net increase in excitability and glutamate release. The derangement of lysosomal processing of proteins is another potential site of ammonia action. This aspect is especially important in view of the growing evidence for the role of the endosomal-lysosomal system in the formation of amyloidogenic fragments from beta-amyloid precursor protein. Ammonia is not considered a primary factor of the disease. However, since hyperammonemia and release of ammonia from the brains of DAT patients is well supported by published observations, ammonia should be taken into account as a factor that contributes to manifestations and the progression of DAT. If elevated ammonia concentrations turn out to be indeed as important in DAT, as is suggested in this review, rational therapeutic avenues can be envisaged that lead to the amelioration of symptoms and progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479596     DOI: 10.1007/bf00969079

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  119 in total

1.  Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.

Authors:  T E Golde; S Estus; L H Younkin; D J Selkoe; S G Younkin
Journal:  Science       Date:  1992-02-07       Impact factor: 47.728

2.  Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease.

Authors:  A W Procter; A M Palmer; P T Francis; S L Lowe; D Neary; E Murphy; R Doshi; D M Bowen
Journal:  J Neurochem       Date:  1988-03       Impact factor: 5.372

3.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

Review 4.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

5.  Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography.

Authors:  R S Frackowiak; C Pozzilli; N J Legg; G H Du Boulay; J Marshall; G L Lenzi; T Jones
Journal:  Brain       Date:  1981-12       Impact factor: 13.501

6.  The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects.

Authors:  L I Benowitz; W Rodriguez; P Paskevich; E J Mufson; D Schenk; R L Neve
Journal:  Exp Neurol       Date:  1989-12       Impact factor: 5.330

7.  Alzheimer's disease: a pathogenic role for aluminosilicate-induced phagocytic free radicals.

Authors:  P H Evans; J Klinowski; E Yano; N Urano
Journal:  Free Radic Res Commun       Date:  1989

8.  Glial fibrillary acidic protein and Alzheimer-type senile dementia.

Authors:  P E Duffy; M Rapport; L Graf
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

9.  Increased tryptophan uptake into the brain in hyperammonemia.

Authors:  C Bachmann; J P Colombo
Journal:  Life Sci       Date:  1983-12-12       Impact factor: 5.037

10.  Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type.

Authors:  S Hoyer; R Nitsch
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

View more
  8 in total

1.  Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.

Authors:  Vicente Felipo; Amparo Urios; Encarna Montesinos; Inmaculada Molina; Maria L Garcia-Torres; Miguel Civera; Juan A Del Olmo; Joaquin Ortega; Jose Martinez-Valls; Miguel A Serra; Norberto Cassinello; Abdallah Wassel; Esperanza Jordá; Carmina Montoliu
Journal:  Metab Brain Dis       Date:  2011-11-10       Impact factor: 3.584

2.  Senile portosystemic hepatic encephalopathy as a treatable dementia-like syndrome.

Authors:  Shoichi Ito; Ryuji Sakakibara; Yasumasa Yoshiyama; Takamichi Hattori
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

3.  Differential inhibition by hyperammonemia of the electron transport chain enzymes in synaptosomes and non-synaptic mitochondria in ornithine transcarbamylase-deficient spf-mice: restoration by acetyl-L-carnitine.

Authors:  K Qureshi; K V Rao; I A Qureshi
Journal:  Neurochem Res       Date:  1998-06       Impact factor: 3.996

4.  In Silico Preliminary Association of Ammonia Metabolism Genes GLS, CPS1, and GLUL with Risk of Alzheimer's Disease, Major Depressive Disorder, and Type 2 Diabetes.

Authors:  Jeddidiah W D Griffin; Ying Liu; Patrick C Bradshaw; Kesheng Wang
Journal:  J Mol Neurosci       Date:  2018-02-13       Impact factor: 3.444

Review 5.  Endogenous ornithine in search for CNS functions and therapeutic applications.

Authors:  N Seiler; G Daune-Anglard
Journal:  Metab Brain Dis       Date:  1993-09       Impact factor: 3.584

6.  Protection against lethal ammonia intoxication: synergism between endogenous ornithine and L-carnitine.

Authors:  S Sarhan; B Knoedgen; N Seiler
Journal:  Metab Brain Dis       Date:  1994-03       Impact factor: 3.584

Review 7.  Ammonia as a Potential Neurotoxic Factor in Alzheimer's Disease.

Authors:  Aida Adlimoghaddam; Mohammad G Sabbir; Benedict C Albensi
Journal:  Front Mol Neurosci       Date:  2016-08-08       Impact factor: 5.639

Review 8.  Amino Acid Catabolism in Alzheimer's Disease Brain: Friend or Foe?

Authors:  Jeddidiah W D Griffin; Patrick C Bradshaw
Journal:  Oxid Med Cell Longev       Date:  2017-02-05       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.